{"transactions":[{"id":746514,"issuer":{"id":8506,"kind":"organization","name":"Silexion Therapeutics Corp"},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Ordinary Shares","published_at":"2026-06-08T20:04:13.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of ordinary shares, par value $0.135 per share (\"ordinary shares\"), reported in this Form 4 reflects an adjustment relative to the Form 4 filed by the Reporting Person on February 23, 2026 due to the 1-for-10 reverse share split effected by the Issuer on May 28, 2026 (which caused the 65,471 ordinary shares, par value $0.0135, beneficially owned by the Reporting Person as reported in that Form 4 to become 6,547 ordinary shares, par value $0.135, prior to the grant reported in this Form 4)."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's services as an officer of the Issuer. The grant was approved by the Issuer's board of directors."}],"balance_after":16547,"source":{"system":"sec-edgar","filing":"0001178913-26-003132","document":"zk2635515.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326003132/zk2635515.xml","form_type":"4"}},{"id":888358,"issuer":{"id":8506,"kind":"organization","name":"Silexion Therapeutics Corp"},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Ordinary Shares","published_at":"2026-02-23T21:14:59.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":64350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of ordinary shares, par value $0.0135 per share (\"ordinary shares\"), reported in this Form 4 reflects adjustments relative to the Form 3 filed by the Reporting Person due to the 1-for 9 and 1-for-15 reverse share splits effected by the Issuer on November 29, 2024 and July 29, 2025, respectively."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's services as an officer of the Issuer. The grant was approved by the Issuer's board of directors."}],"balance_after":65471,"source":{"system":"sec-edgar","filing":"0001178913-26-000600","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326000600/ownership.xml","form_type":"4"}},{"id":3215115,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Country Manager"}}],"security":"Stock Options","published_at":"2020-03-11T21:56:34.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":57086,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2021 and 6.25% every three months thereafter) ending March 31, 2024."}],"balance_after":57086,"derivative":{"exercise_price":6.81,"expiration_date":"2030-02-24","underlying":"Common Stock","underlying_shares":57086},"source":{"system":"sec-edgar","filing":"0001209191-20-018225","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018225/doc4.xml","form_type":"4"}},{"id":3215114,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Country Manager"}}],"security":"Stock Options","published_at":"2020-03-11T21:56:34.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":56275,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2020 and 6.25% every three months thereafter) ending March 31, 2023."}],"balance_after":56275,"derivative":{"exercise_price":6.44,"expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":56275},"source":{"system":"sec-edgar","filing":"0001209191-20-018225","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018225/doc4.xml","form_type":"4"}},{"id":3215113,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Country Manager"}}],"security":"Stock Options","published_at":"2020-03-11T21:56:34.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":20789,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The ordinary shares underlying this option vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending March 31, 2022."}],"balance_after":20789,"derivative":{"exercise_price":10.81,"expiration_date":"2028-02-27","underlying":"Common Stock","underlying_shares":20789},"source":{"system":"sec-edgar","filing":"0001209191-20-018225","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018225/doc4.xml","form_type":"4"}},{"id":3215112,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Country Manager"}}],"security":"Stock Options","published_at":"2020-03-11T21:56:34.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":116231,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The ordinary shares underlying this option vest over a period of four years (25% on August 8, 2018 and 6.25% every three months thereafter) ending September 30, 2021."}],"balance_after":116231,"derivative":{"exercise_price":8.81,"expiration_date":"2027-08-08","underlying":"Common Stock","underlying_shares":116231},"source":{"system":"sec-edgar","filing":"0001209191-20-018225","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018225/doc4.xml","form_type":"4"}},{"id":3215111,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Country Manager"}}],"security":"Stock Options","published_at":"2020-03-11T21:56:34.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":35774,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The ordinary shares underlying this option vest over a period of four years (25% on January 1, 2018 and 6.25% every three months thereafter) ending March 31, 2021."}],"balance_after":35774,"derivative":{"exercise_price":17.4,"expiration_date":"2027-01-01","underlying":"Common Stock","underlying_shares":35774},"source":{"system":"sec-edgar","filing":"0001209191-20-018225","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018225/doc4.xml","form_type":"4"}},{"id":3215110,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Country Manager"}}],"security":"Stock Options","published_at":"2020-03-11T21:56:34.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":35544,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The ordinary shares underlying this option vest over a period of four years (25% on March 1, 2017 and 6.25% every three months thereafter) ending March 31, 2020."}],"balance_after":35544,"derivative":{"exercise_price":10.7,"expiration_date":"2026-03-01","underlying":"Common Stock","underlying_shares":35544},"source":{"system":"sec-edgar","filing":"0001209191-20-018225","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018225/doc4.xml","form_type":"4"}},{"id":3215109,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Country Manager"}}],"security":"Stock Options","published_at":"2020-03-11T21:56:34.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":119667,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."}],"balance_after":119667,"derivative":{"exercise_price":12.04,"exercise_date":"2020-03-09","expiration_date":"2025-11-10","underlying":"Common Stock","underlying_shares":119667},"source":{"system":"sec-edgar","filing":"0001209191-20-018225","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018225/doc4.xml","form_type":"4"}},{"id":3215108,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Country Manager"}}],"security":"Stock Options","published_at":"2020-03-11T21:56:34.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":10663,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."}],"balance_after":10663,"derivative":{"exercise_price":11.43,"exercise_date":"2020-03-09","expiration_date":"2025-01-15","underlying":"Common Stock","underlying_shares":10663},"source":{"system":"sec-edgar","filing":"0001209191-20-018225","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018225/doc4.xml","form_type":"4"}},{"id":3215107,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Country Manager"}}],"security":"Stock Options","published_at":"2020-03-11T21:56:34.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":14291,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."}],"balance_after":14291,"derivative":{"exercise_price":9.22,"exercise_date":"2020-03-09","expiration_date":"2024-11-19","underlying":"Common Stock","underlying_shares":14291},"source":{"system":"sec-edgar","filing":"0001209191-20-018225","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018225/doc4.xml","form_type":"4"}},{"id":3215106,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Country Manager"}}],"security":"Stock Options","published_at":"2020-03-11T21:56:34.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":3239,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."}],"balance_after":3239,"derivative":{"exercise_price":3.25,"exercise_date":"2020-03-09","expiration_date":"2024-03-31","underlying":"Common Stock","underlying_shares":3239},"source":{"system":"sec-edgar","filing":"0001209191-20-018225","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018225/doc4.xml","form_type":"4"}},{"id":3215105,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Country Manager"}}],"security":"Common Stock","published_at":"2020-03-11T21:56:34.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":69012,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."}],"balance_after":77351,"source":{"system":"sec-edgar","filing":"0001209191-20-018225","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018225/doc4.xml","form_type":"4"}},{"id":3215104,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Country Manager"}}],"security":"Common Stock","published_at":"2020-03-11T21:56:34.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":8339,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."}],"balance_after":8339,"source":{"system":"sec-edgar","filing":"0001209191-20-018225","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018225/doc4.xml","form_type":"4"}},{"id":3214993,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Country Manager"}}],"security":"Options","published_at":"2020-03-11T17:38:36.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":96365,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each option to purchase a Foamix Share (a \"Foamix Option\") was converted into an option to purchase Menlo Common Stock (an \"Adjusted Option\") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2021 and 6.25% every three months thereafter) ending March 31, 2024."}],"balance_after":0,"derivative":{"exercise_price":4.03,"expiration_date":"2030-02-24","underlying":"Ordinary Shares","underlying_shares":96365},"source":{"system":"sec-edgar","filing":"0001209191-20-018195","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018195/doc4.xml","form_type":"4"}},{"id":3214992,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Country Manager"}}],"security":"Options","published_at":"2020-03-11T17:38:36.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":94996,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each option to purchase a Foamix Share (a \"Foamix Option\") was converted into an option to purchase Menlo Common Stock (an \"Adjusted Option\") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2020 and 6.25% every three months thereafter) ending March 31, 2023."}],"balance_after":0,"derivative":{"exercise_price":3.81,"expiration_date":"2029-01-01","underlying":"Ordinary Shares","underlying_shares":94996},"source":{"system":"sec-edgar","filing":"0001209191-20-018195","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018195/doc4.xml","form_type":"4"}},{"id":3214991,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Country Manager"}}],"security":"Options","published_at":"2020-03-11T17:38:36.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":35093,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each option to purchase a Foamix Share (a \"Foamix Option\") was converted into an option to purchase Menlo Common Stock (an \"Adjusted Option\") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The ordinary shares underlying this option vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending March 31, 2022."}],"balance_after":0,"derivative":{"exercise_price":6.4,"expiration_date":"2028-02-27","underlying":"Ordinary Shares","underlying_shares":35093},"source":{"system":"sec-edgar","filing":"0001209191-20-018195","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018195/doc4.xml","form_type":"4"}},{"id":3214990,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Country Manager"}}],"security":"Options","published_at":"2020-03-11T17:38:36.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":196205,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each option to purchase a Foamix Share (a \"Foamix Option\") was converted into an option to purchase Menlo Common Stock (an \"Adjusted Option\") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The ordinary shares underlying this option vest over a period of four years (25% on August 8, 2018 and 6.25% every three months thereafter) ending September 30, 2021."}],"balance_after":0,"derivative":{"exercise_price":5.22,"expiration_date":"2027-08-08","underlying":"Ordinary Shares","underlying_shares":196205},"source":{"system":"sec-edgar","filing":"0001209191-20-018195","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018195/doc4.xml","form_type":"4"}},{"id":3214989,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Country Manager"}}],"security":"Options","published_at":"2020-03-11T17:38:36.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":60389,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each option to purchase a Foamix Share (a \"Foamix Option\") was converted into an option to purchase Menlo Common Stock (an \"Adjusted Option\") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The ordinary shares underlying this option vest over a period of four years (25% on January 1, 2018 and 6.25% every three months thereafter) ending March 31, 2021."}],"balance_after":0,"derivative":{"exercise_price":10.31,"expiration_date":"2027-01-01","underlying":"Ordinary Shares","underlying_shares":60389},"source":{"system":"sec-edgar","filing":"0001209191-20-018195","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018195/doc4.xml","form_type":"4"}},{"id":3214988,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Country Manager"}}],"security":"Options","published_at":"2020-03-11T17:38:36.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each option to purchase a Foamix Share (a \"Foamix Option\") was converted into an option to purchase Menlo Common Stock (an \"Adjusted Option\") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The ordinary shares underlying this option vest over a period of four years (25% on March 1, 2017 and 6.25% every three months thereafter) ending March 31, 2020."}],"balance_after":0,"derivative":{"exercise_price":6.34,"expiration_date":"2026-03-01","underlying":"Ordinary Shares","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-20-018195","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018195/doc4.xml","form_type":"4"}},{"id":3214987,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Country Manager"}}],"security":"Options","published_at":"2020-03-11T17:38:36.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":202004,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each option to purchase a Foamix Share (a \"Foamix Option\") was converted into an option to purchase Menlo Common Stock (an \"Adjusted Option\") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The Options vested over a period of four years from November 10, 2015 (25% on the first anniversary of such date and 6.25% every three months thereafter)."}],"balance_after":0,"derivative":{"exercise_price":7.13,"expiration_date":"2025-11-10","underlying":"Ordinary Shares","underlying_shares":202004},"source":{"system":"sec-edgar","filing":"0001209191-20-018195","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018195/doc4.xml","form_type":"4"}},{"id":3214986,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Country Manager"}}],"security":"Options","published_at":"2020-03-11T17:38:36.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":18000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each option to purchase a Foamix Share (a \"Foamix Option\") was converted into an option to purchase Menlo Common Stock (an \"Adjusted Option\") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Options vested over a period of four years from January 15, 2015 (25% on the first anniversary of such date and 6.25% every three months thereafter)."}],"balance_after":0,"derivative":{"exercise_price":6.77,"expiration_date":"2025-01-15","underlying":"Ordinary Shares","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-20-018195","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018195/doc4.xml","form_type":"4"}},{"id":3214985,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Country Manager"}}],"security":"Options","published_at":"2020-03-11T17:38:36.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":24125,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each option to purchase a Foamix Share (a \"Foamix Option\") was converted into an option to purchase Menlo Common Stock (an \"Adjusted Option\") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Options vested over a period of four years from November 19, 2014 (20% on such date and 5% every three months thereafter)."}],"balance_after":0,"derivative":{"exercise_price":5.46,"expiration_date":"2024-11-19","underlying":"Ordinary Shares","underlying_shares":24125},"source":{"system":"sec-edgar","filing":"0001209191-20-018195","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018195/doc4.xml","form_type":"4"}},{"id":3214984,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Country Manager"}}],"security":"Options","published_at":"2020-03-11T17:38:36.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":5469,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each option to purchase a Foamix Share (a \"Foamix Option\") was converted into an option to purchase Menlo Common Stock (an \"Adjusted Option\") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Options vested over a period of four years from March 31, 2014 (20% on such date and 5% every three months thereafter)."}],"balance_after":0,"derivative":{"exercise_price":1.92,"expiration_date":"2024-03-31","underlying":"Ordinary Shares","underlying_shares":5469},"source":{"system":"sec-edgar","filing":"0001209191-20-018195","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018195/doc4.xml","form_type":"4"}},{"id":3214983,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Country Manager"}}],"security":"Ordinary Shares","published_at":"2020-03-11T17:38:36.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":116501,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents Foamix restricted stock unit awards (\"Foamix RSUs\") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an \"Adjusted RSU Award\") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-018195","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018195/doc4.xml","form_type":"4"}},{"id":3214982,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Country Manager"}}],"security":"Ordinary Shares","published_at":"2020-03-11T17:38:36.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":14077,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 9, 2020 (the \"Closing Date\"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the \"Merger Agreement\"), by and among Menlo Therapeutics Inc., a Delaware corporation (\"Menlo\"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo (\"Merger Sub\"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each ordinary share, par value NIS 0.16 per share, of Foamix (\"Foamix Shares\") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the \"Exchange Ratio\") of common stock of Menlo (\"Menlo Common Stock\") and (ii) one contingent stock right (continued in footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(a \"CSR\"; and collectively, the \"CSRs\") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the \"CSR Agreement\"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the \"Merger Consideration\"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement."}],"balance_after":116501,"source":{"system":"sec-edgar","filing":"0001209191-20-018195","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018195/doc4.xml","form_type":"4"}},{"id":3251936,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Country Manager"}}],"security":"Options","published_at":"2020-02-24T18:38:30.000Z","date":"2020-02-24","kind":"grant","acquired":true,"shares":96365,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Each option represents a contingent right to purchase one ordinary share of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The ordinary shares underlying these options vest over a 4 year period, with 25% vesting on the first anniversary of the last day of the calendar quarter in which the grant occurred and 6.25% vesting on the last day of each subsequent calendar quarter, ending March 31, 2024."}],"balance_after":96365,"derivative":{"exercise_price":4.03,"expiration_date":"2030-02-24","underlying":"Ordinary Shares","underlying_shares":96365},"source":{"system":"sec-edgar","filing":"0001209191-20-012196","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120012196/doc4.xml","form_type":"4"}},{"id":3251935,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Country Manager"}}],"security":"Ordinary Shares","published_at":"2020-02-24T18:38:30.000Z","date":"2020-02-24","kind":"grant","acquired":true,"shares":41299,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"The ordinary shares underlying this restricted share unit award vest over a 4 year period, with 25% vesting on the first anniversary of the last day of the calendar quarter in which the grant occurred and 6.25% vesting on the last day of each subsequent calendar quarter, ending March 31, 2024."}],"balance_after":130578,"source":{"system":"sec-edgar","filing":"0001209191-20-012196","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120012196/doc4.xml","form_type":"4"}},{"id":3417176,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Country Manager"}}],"security":"Ordinary Shares","published_at":"2019-09-11T17:12:53.000Z","date":"2019-09-10","kind":"sale","acquired":false,"shares":34392,"price":3.5001,"value":120375.4392,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2019."}],"balance_after":89279,"source":{"system":"sec-edgar","filing":"0001209191-19-049203","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919119049203/doc4.xml","form_type":"4"}},{"id":3417175,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Country Manager"}}],"security":"Ordinary Shares","published_at":"2019-09-11T17:12:53.000Z","date":"2019-09-09","kind":"sale","acquired":false,"shares":9420,"price":3.5022,"value":32990.724,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2019."}],"balance_after":123671,"source":{"system":"sec-edgar","filing":"0001209191-19-049203","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919119049203/doc4.xml","form_type":"4"}},{"id":3707333,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Country Manager"}}],"security":"Option (right to buy)","published_at":"2019-01-03T16:09:47.000Z","date":"2019-01-01","kind":"grant","acquired":true,"shares":94996,"price":3.81,"value":361934.76,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The ordinary shares underlying these options vest over a period of four years from the end of the calendar quarter in which the grant was made (25% on March 31, 2020, and 6.25% every three months thereafter on the last day of the quarter) ending March 31, 2023, subject to the reporting person's continuous service with the Issuer as of each such vesting date"}],"balance_after":94996,"derivative":{"exercise_price":3.81,"expiration_date":"2029-01-01","underlying":"Ordinary Shares","underlying_shares":94996},"source":{"system":"sec-edgar","filing":"0001178913-19-000050","document":"zk1922435.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891319000050/zk1922435.xml","form_type":"4"}},{"id":3707332,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Country Manager"}}],"security":"Ordinary Shares","published_at":"2019-01-03T16:09:47.000Z","date":"2019-01-01","kind":"grant","acquired":true,"shares":40712,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer. The ordinary shares underlying this restricted share unit award vest over a period of four years from the end of the calendar quarter in which the grant was made (25% on March 31, 2020, and 6.25% every three months thereaf-ter on the last day of the quarter) ending March 31, 2023, subject to the reporting person's continuous service with the Issuer as of each such vesting date"}],"balance_after":133091,"source":{"system":"sec-edgar","filing":"0001178913-19-000050","document":"zk1922435.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891319000050/zk1922435.xml","form_type":"4"}},{"id":4026376,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Country Manager"}}],"security":"Options","published_at":"2018-02-28T16:13:57.000Z","date":"2018-02-27","kind":"grant","acquired":true,"shares":35093,"price":6.4,"value":224595.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Each option represents a contingent right to purchase one ordinary share of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The ordinary shares underlying these options vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022."}],"balance_after":35093,"derivative":{"exercise_price":6.4,"expiration_date":"2028-02-27","underlying":"Ordinary Shares","underlying_shares":35093},"source":{"system":"sec-edgar","filing":"0001178913-18-000728","document":"zk1821310.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318000728/zk1821310.xml","form_type":"4"}},{"id":4026375,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Country Manager"}}],"security":"Ordinary Shares","published_at":"2018-02-28T16:13:57.000Z","date":"2018-02-27","kind":"grant","acquired":true,"shares":11698,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer."}],"balance_after":92379,"source":{"system":"sec-edgar","filing":"0001178913-18-000728","document":"zk1821310.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318000728/zk1821310.xml","form_type":"4"}},{"id":4090760,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Country Manager"}}],"security":"Restricted Share Units","published_at":"2018-01-24T20:27:38.000Z","date":"2018-01-15","kind":"exercise","acquired":false,"shares":562,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The ordinary shares underlying this restricted share unit award vest in equal installments every three months over the vesting period beginning January 15, 2018 and ending January 15, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The ordinary shares underlying this restricted share unit award vest in equal installments every three months over the vesting period beginning January 15, 2018 and ending January 15, 2019."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"This class of restricted share units is included in Column 5 of Table I above."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Ordinary Shares","underlying_shares":562},"source":{"system":"sec-edgar","filing":"0001178913-18-000267","document":"a1821073.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318000267/a1821073.xml","form_type":"4"}},{"id":4090759,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Country Manager"}}],"security":"Restricted Share Units","published_at":"2018-01-24T20:27:38.000Z","date":"2018-01-01","kind":"exercise","acquired":false,"shares":5032,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on January 1, 2018 and 6.25% every three months thereafter) ending January 1, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on January 1, 2018 and 6.25% every three months thereafter) ending January 1, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"This class of restricted share units is included in Column 5 of Table I above."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Ordinary Shares","underlying_shares":5032},"source":{"system":"sec-edgar","filing":"0001178913-18-000267","document":"a1821073.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318000267/a1821073.xml","form_type":"4"}},{"id":4090758,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Country Manager"}}],"security":"Ordinary Shares","published_at":"2018-01-24T20:27:38.000Z","date":"2018-01-15","kind":"exercise","acquired":true,"shares":562,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The issuer's method of reporting restricted share units has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, this amount includes (i) 7,277 ordinary shares previously reported in Table I of the reporting person's Form 3 (ii) 5,032 ordinary shares underlying restricted share units that vested on January 1, 2018 (iii) 562 ordinary shares underlying restricted share units that vested on January 15, 2018 and (iv) 67,810 ordinary shares subject to unvested restricted share units that were previously reported in Table II of the reporting person's Form 3 as a derivative security."}],"balance_after":80681,"source":{"system":"sec-edgar","filing":"0001178913-18-000267","document":"a1821073.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318000267/a1821073.xml","form_type":"4"}},{"id":4090757,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":40577,"kind":"person","name":"Hadar Ilan","position":1,"cik":"0001727727","reported_name":"Hadar Ilan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Country Manager"}}],"security":"Ordinary Shares","published_at":"2018-01-24T20:27:38.000Z","date":"2018-01-01","kind":"exercise","acquired":true,"shares":5032,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The issuer's method of reporting restricted share units has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, this amount includes (i) 7,277 ordinary shares previously reported in Table I of the reporting person's Form 3 (ii) 5,032 ordinary shares underlying restricted share units that vested on January 1, 2018 (iii) 562 ordinary shares underlying restricted share units that vested on January 15, 2018 and (iv) 67,810 ordinary shares subject to unvested restricted share units that were previously reported in Table II of the reporting person's Form 3 as a derivative security."}],"balance_after":80681,"source":{"system":"sec-edgar","filing":"0001178913-18-000267","document":"a1821073.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318000267/a1821073.xml","form_type":"4"}}]}